Compare Dicks Sporting Goods Inc (DKS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Dicks Sporting Goods Inc trades at $134.34 (market cap $12.92B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.9× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays the higher dividend (3.81%). Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| DKS | REGN | |
|---|---|---|
Market Cap | $12.92B | $76.14B |
Volume | 2,077,432 | 500,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $852.03 |
52-Week Low | $121.15 | $557.73 |
Typical Hold Time | 19 Days | 107 Days |
Enterprise Value | $19.97B | $70.85B |
Dividend Yield | 3.81% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $131.18, down 2.74% on the day, with a bearish technical signal from moving averages and oscillators. The company shows solid profitability with an 18.47% ROE and a net income margin of 3.97%, though recent earnings missed expectations in Q2 2026. Revenue grew to $13.44B in 2025, but profit margins are projected to compress in 2026. A securities class action lawsuit filed for the period September 2025 to August 2026 adds legal overhang.
The stock presents a mixed outlook; strong analyst consensus with a $153.30 price target suggests 17% upside, supported by a reasonable P/E of 14.48. However, near-term risks include the class action litigation, technical bearishness, and margin pressure. The dividend increase to $1.25 signals confidence, but investors must weigh legal and operational headwinds against valuation appeal.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
